ProNGF Mutant Cleavage Site Engineering for Homogeneous Beta-NGF Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing beta-NGF suffer from low yields, inefficiency, and the production of inhomogeneous products due to the use of trypsin as a protease, which requires high enzyme amounts and complicates purification.
Innovation Solution
A novel proNGF mutant with substitutions at the native protease cleavage site R1SK3R4, using non-basic amino acids and Histidine, is developed to enhance trypsin cleavage efficiency, allowing for low enzyme usage and reduced purification challenges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If trypsin is used as a protease for producing beta-NGF, then the cleavage reaction can proceed, but high enzyme amounts are required and purification becomes complicated
Solution Approach 1:
The patent extracts and removes the problematic basic amino acids (Arginine at position 101 and Lysine at position 103) from the protease cleavage site sequence. By substituting these basic amino acids with non-basic amino acids, the patent eliminates the need for high amounts of trypsin and simplifies the purification process, as the mutated sequence no longer contains multiple trypsin cleavage sites that would complicate product purification.
Solution Approach 2:
The patent changes the chemical parameters of the cleavage site sequence by substituting basic amino acids with non-basic amino acids. This parameter change (from basic to non-basic) fundamentally alters the interaction between the substrate and trypsin, reducing enzyme requirements and simplifying downstream purification while maintaining productive cleavage at the desired site.
2Productivity
If trypsin is used as a protease for producing beta-NGF, then the cleavage reaction can proceed, but the production of inhomogeneous products occurs
Solution Approach 1:
The patent removes unwanted cleavage sites by extracting and substituting the basic amino acids at positions 101 and 103. This leaves only the essential Arginine at position 104 as a cleavage site, ensuring that trypsin acts at a single specific location and produces homogeneous beta-NGF products without unwanted fragments or variants.
Solution Approach 2:
The patent applies local quality modification by specifically changing only the amino acid composition at the cleavage site (positions 101-104) while leaving the rest of the proNGF sequence unchanged. This localized substitution ensures that cleavage occurs with high precision at the intended site, producing uniform products with consistent quality.
3Speed
If high amounts of trypsin are used for cleavage, then the cleavage reaction efficiency increases, but the purification process becomes more difficult
Solution Approach 1:
The patent changes the substrate parameters by substituting basic amino acids with non-basic amino acids at positions 101 and 103. This parameter change allows the cleavage reaction to proceed efficiently with minimal trypsin amounts, as the mutated sequence becomes highly specific for trypsin action. The reduced enzyme quantity directly simplifies the purification process by reducing background contamination.
4Reliability
If multiple basic amino acids are present at the cleavage site, then protease recognition is enhanced, but multiple cleavage sites are created leading to inhomogeneous products
Solution Approach 1:
The patent applies local quality modification by preserving the basic amino acid Arginine at position 104 (which is essential for protease recognition and cleavage) while substituting the basic amino acids at positions 101 and 103 with non-basic amino acids. This selective local modification maintains reliable protease recognition at the intended cleavage site while eliminating unwanted alternative cleavage sites, ensuring manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in high-yield, homogeneous beta-NGF production with improved cleavage efficiency and reduced purification issues, achieving robust and scalable production.
Implementation Method 1
The prosequence of proNGF is cleaved off whereby active beta-NGF is obtained
Data Source
AI summary
The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.